SELECTIMMUNE PHARMA
SelectImmune Pharma engages in the development and manufacture of immune enhancers as an alternative to antibiotics.
SELECTIMMUNE PHARMA
Industry:
Biopharma Health Care Health Diagnostics Life Science Manufacturing Medical
Founded:
2017-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.selectimmune.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Apache Wordpress Plugins Mobile Non Scaleable Content PHP
Similar Organizations
Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems.
Sidefarma
Sidefarma engages in the development and manufacture of medicines and other pharmaceutical products.
Wockhardt Bio AG
Wockhardt Bio develops, manufactures and markets pharmaceutical and bio-pharmaceutical formulations.
Current Employees Featured
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-26 | SelectImmune Pharma appoints acting CEO |
Official Site Inspections
http://www.selectimmune.com Semrush global rank: 5.36 M Semrush visits lastest month: 1.56 K
- Host name: 199.59.243.227
- IP address: 199.59.243.227
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "SelectImmune Pharma"
SelectImmune Pharma - Crunchbase Company Profile & Funding
Organization. SelectImmune Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. SelectImmune Pharma engages in …See details»
Hamlet Pharma and SelectImmune Pharma merge to ... - Hamlet …
Pharma's B share, the offer values SelectImmune at SEK 3.06 per share, which means a premium of approximately 63.25 percent compared to the volume-weighted average price paid …See details»
About Hamlet Biopharma - Hamlet BioPharma
The two pharmaceutical companies Hamlet Pharma AB and SelectImmune Pharma AB, listed on the Spotlight Stock Market, has per 2023-05-17 been merged to create a powerful …See details»
SelectImmune Pharma Company Profile 2024: …
SelectImmune Pharma AB is an innovative biotech company with five well-documented strategies for infection control without antibiotics. The research team behind the innovations has discovered new molecules which selectively …See details»
Merger Hamlet-SelectImmune - Hamlet BioPharma
Mar 31, 2023 Merger Hamlet-SelectImmune; hamletpharma.com; selectimmune.com. Årsredovisningar. 20/21; 21/22; 22/23; Hamlet Pharma AB. BMC D10 Klinikgatan 32 SE-222 …See details»
SelectImmune Pharma strengthens its organization through the ...
Fredrik Herslow, CEO SelectImmune Pharma, +46 705 91 15 44 [email protected] SelectImmune Pharma is a pharmaceutical company …See details»
Q3 - Hamlet BioPharma
SelectImmune's shareholders. Through the Merger and Acquisition of Linnane Projects AB ("Linnane Projects"), the various sub-projects are established in an organization that can …See details»
SelectImmune Pharma - Funding, Financials, Valuation & Investors
Jun 26, 2019 Organization. SelectImmune Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... IPO & Stock Price. …See details»
PRESS RELEASE, May 19, 2020 - SelectImmune
Acting CEO, SelectImmune Pharma AB Tel: +46 708 48 42 10 E-mail: [email protected] SelectImmune Pharma is a pharmaceutical company whose …See details»
SelectImmune Pharma - Tech Stack, Apps, Patents & Trademarks
Organization. SelectImmune Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 1. Monthly …See details»
Clinical study ready to start – a new treatment option
SelectImmune Pharma has established the study organization in Sweden and secured access to placebo through an agreement with Sobi (Swedish Orphan Biovitrum). "It is important to really …See details»
SelectImmune Pharma Interim report Q1 2022/2023 - mfn.se
Nov 16, 2022 SelectImmune Pharma has patented the treatment with IL-1RA for the indications of cystitis and bladder pain. Sobi will provide the study drug and placebo for the controlled …See details»
Hamlet Pharma AB (publ): Q3 Interim Report January 2023 - Placera
May 26, 2023 Hamlet Pharma has worked intensely to develop the proposed merger with SelectImmune Pharma AB, creating Hamlet Biopharma, a strong pharmaceutical company …See details»
SelectImmune Pharma Interim report Q1 2022/2023 - Cision News
Nov 16, 2022 SELECTIMMUNE PHARMA IN BRIEF • SelectImmune Pharma is an innovative biotech company that. ... The study organization is highly competent and the collection of …See details»
SelectImmune Collaborates with Lonza to Develop an …
Jun 21, 2021 Lund, Sweden and Basel, Switzerland, 21 June 2021 – SelectImmune Pharma, a pharmaceutical company developing novel immunotherapeutics and alternatives to antibiotics, …See details»
20221114 PR SI ENG - selectimmune.com
Nov 14, 2022 CEO (acting), SelectImmune Pharma AB Tel: +46 733 38 13 44 E-mail: [email protected] Catharina Svanborg Chairman SelectImmune Pharma …See details»
INTERIM REPORT OCTOBER 1st 2022 – DECEMBER 31st 2022
Feb 23, 2023 SELECTIMMUNE PHARMA IN BRIEF SelectImmune Pharma is an innovative biotech company that. ... The efficient study organization includes physicians, monitors, other …See details»
Hamlet Pharma and SelectImmune Pharma merge to create an …
Mar 31, 2023 The long-term goal of the company group consisting of Hamlet Pharma, SelectImmune Pharma and Linnane Pharma is to commercialize a broad portfolio of …See details»
Hamlet Pharma and SelectImmune Pharma merge to create an …
Pharma's B share, the offer values SelectImmune at SEK 3.06 per share, which means a premium of approximately 63.25 percent compared to the volume-weighted average price paid …See details»
Start of the SelectImmune Pharma Phase II trial of targeted ...
SelectImmune Pharma is proud to report that the Phase II trial of the IL-1 receptor antagonist (IL-1RA) in patients with recurrent acute cystitis has started. ... study organization finalized, …See details»